表紙
市場調查報告書

寡核苷酸合成的全球市場:2019年∼2023年

Oligonucleotide Synthesis Market by End-users and Geography - Forecast and Analysis 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 913031
出版日期 內容資訊 英文 150 Pages
訂單完成後即時交付
價格
Back to Top
寡核苷酸合成的全球市場:2019年∼2023年 Oligonucleotide Synthesis Market by End-users and Geography - Forecast and Analysis 2019-2023
出版日期: 2019年09月27日內容資訊: 英文 150 Pages
簡介

全球寡核苷酸合成市場上,作為醫藥品及生物科技部門的研究活動的增加,治療及診斷工具寡核苷酸合成的利用的增加,並且寡核苷酸合成的技術創新的登場等成為成長促進因素,在預測期間內預計將以10%以上的年複合成長率擴大。但,核酸醫藥相關的法規的問題,寡核苷酸分子的多樣性,寡核苷酸的有效給藥的課題等要素,可能妨礙在預測期間內寡核苷酸合成產業的成長。

本報告提供全球寡核苷酸合成市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各終端用戶

  • 市場區隔:各終端用戶
  • 各終端用戶比較:市場規模及預測(2018年∼2023年)
  • 製藥及生物科技企業
  • 研究機關及學術機構
  • 診斷研究所
  • 醫院
  • 市場機會:各終端用戶

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 新的寡核苷酸治療藥的研究開發的關注高漲
  • 寡核苷酸開發新藥的策略性合作和合作關係
  • 低成本高性能的寡核苷酸合成的需求高漲

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Agilent Technologies Inc.
  • Danaher Corp.
  • General Electric Co.
  • GenScript Biotech Corp.
  • KANEKA
  • Merck KGaA
  • 日東電工
  • QIAGEN NV
  • Sarepta Therapeutics Inc.
  • Thermo Fisher Scientific Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR32105

About this market

Technavio's oligonucleotide synthesis market analysis considers sales from pharmaceutical and biotechnology companies, research and academic institutes, diagnostic laboratories, and hospital end-users. Our analysis also considers the sales of oligonucleotide synthesis in Asia, Europe, North America, and ROW. In 2018, the pharmaceutical and biotechnology companies segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increase in research on the development of oligonucleotide therapeutics will play a significant role in the pharmaceutical and biotechnology companies segment to maintain its market position. Also, our global oligonucleotide synthesis market report looks at factors such as the increasing research activities in the pharmaceutical and biotechnology sectors, increasing use of oligonucleotides as therapeutic and diagnostic tools, and emergence of technological innovations in oligonucleotide synthesis. However, regulatory issues associated with oligonucleotide therapeutics, diversity in oligonucleotide molecules, and challenges in effective oligonucleotide delivery may hamper the growth of the oligonucleotide synthesis industry over the forecast period.

Overview

Increasing research activities in the pharmaceutical and biotechnology sectors

The increasing prevalence of chronic and life-threatening diseases has prompted pharmaceutical companies and research firms to focus on R&D activities for the development of effective therapeutics. As a result, advances in life sciences research is leading to an improved understanding of biological systems. The development of oligonucleotide synthesis technologies has helped pharmaceutical and biotechnology researchers with molecular-level development, design, and modification of biological systems. The increasing research activities in the pharmaceutical and biotechnology sectors will lead to the expansion of the global oligonucleotide synthesis market at a CAGR of over 10% during the forecast period.

Increasing focus on R&D of new oligonucleotide therapies

Pharmaceutical and biotechnological companies are focusing on R&D of new oligonucleotide drugs due to the presence of the limited number of approved drugs. Oligonucleotides efficiently target disease-relevant proteins and genes that are inaccessible by small-molecule drugs and biologic drugs. Recent advances have helped overcome challenges associated with the administration, cellular uptake, biodistribution, and side effects of oligonucleotide therapies. Currently, many oligonucleotide therapeutics are in various stages of clinical trials for the treatment of many diseases, including viral infections, rare genetic disorders, neural and neuromuscular conditions, and cancers. The presence of these drugs and increase in R&D is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global oligonucleotide synthesis market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global oligonucleotide synthesis market is moderately concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading oligonucleotide synthesis manufacturers, that include Agilent Technologies Inc., Danaher Corp., General Electric Co., GenScript Biotech Corp., Kaneka Corp., Merck KGaA, Nitto Denko Corp., QIAGEN NV, Sarepta Therapeutics Inc., and Thermo Fisher Scientific Inc.

Also, the oligonucleotide synthesis market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY END-USER

  • Market segmentation by end-user
  • Comparison by end-user
  • Pharmaceutical and biotechnology companies - Market size and forecast
  • 2018-2023
  • Research and academic institutes - Market size and forecast 2018-2023
  • Diagnostic laboratories - Market size and forecast 2018-2023
  • Hospitals - Market size and forecast 2018-2023
  • Market opportunity by end-user

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing focus on R&D of new oligonucleotide therapeutics
  • Strategic collaborations and partnerships for oligonucleotide drug discovery and development
  • Rise in demand for low-cost and high-throughput oligonucleotide synthesis

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Agilent Technologies Inc.
  • Danaher Corp.
  • General Electric Co.
  • GenScript Biotech Corp.
  • Kaneka Corp.
  • Merck KGaA
  • Nitto Denko Corp.
  • QIAGEN NV
  • Sarepta Therapeutics Inc.
  • Thermo Fisher Scientific Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global healthcare market
  • Exhibit 03: Segments of global healthcare market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: End-user - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by end-user
  • Exhibit 20: Pharmaceutical and biotechnology companies - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Pharmaceutical and biotechnology companies - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Research and academic institutes - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Research and academic institutes - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Diagnostic laboratories - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Diagnostic laboratories - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Hospitals - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Hospitals - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: Market opportunity by end-user
  • Exhibit 29: Customer landscape
  • Exhibit 30: Market share by geography 2018-2023 (%)
  • Exhibit 31: Geographic comparison
  • Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Agilent Technologies Inc. - Vendor overview
  • Exhibit 49: Agilent Technologies Inc. - Business segments
  • Exhibit 50: Agilent Technologies Inc. - Organizational developments
  • Exhibit 51: Agilent Technologies Inc. - Geographic focus
  • Exhibit 52: Agilent Technologies Inc. - Segment focus
  • Exhibit 53: Agilent Technologies Inc. - Key offerings
  • Exhibit 54: Danaher Corp. - Vendor overview
  • Exhibit 55: Danaher Corp. - Business segments
  • Exhibit 56: Danaher Corp. - Organizational developments
  • Exhibit 57: Danaher Corp. - Geographic focus
  • Exhibit 58: Danaher Corp. - Segment focus
  • Exhibit 59: Danaher Corp. - Key offerings
  • Exhibit 60: General Electric Co. - Vendor overview
  • Exhibit 61: General Electric Co. - Business segments
  • Exhibit 62: General Electric Co. - Organizational developments
  • Exhibit 63: General Electric Co. - Geographic focus
  • Exhibit 64: General Electric Co. - Segment focus
  • Exhibit 65: General Electric Co. - Key offerings
  • Exhibit 66: GenScript Biotech Corp. - Vendor overview
  • Exhibit 67: GenScript Biotech Corp. - Business segments
  • Exhibit 68: GenScript Biotech Corp. - Organizational developments
  • Exhibit 69: GenScript Biotech Corp. - Geographic focus
  • Exhibit 70: GenScript Biotech Corp. - Segment focus
  • Exhibit 71: GenScript Biotech Corp. - Key offerings
  • Exhibit 72: Kaneka Corp. - Vendor overview
  • Exhibit 73: Kaneka Corp. - Business segments
  • Exhibit 74: Kaneka Corp. - Organizational developments
  • Exhibit 75: Kaneka Corp. - Geographic focus
  • Exhibit 76: Kaneka Corp. - Segment focus
  • Exhibit 77: Kaneka Corp. - Key offerings
  • Exhibit 78: Merck KGaA - Vendor overview
  • Exhibit 79: Merck KGaA - Business segments
  • Exhibit 80: Merck KGaA - Organizational developments
  • Exhibit 81: Merck KGaA - Geographic focus
  • Exhibit 82: Merck KGaA - Segment focus
  • Exhibit 83: Merck KGaA - Key offerings
  • Exhibit 84: Nitto Denko Corp. - Vendor overview
  • Exhibit 85: Nitto Denko Corp. - Business segments
  • Exhibit 86: Nitto Denko Corp. - Organizational developments
  • Exhibit 87: Nitto Denko Corp. - Geographic focus
  • Exhibit 88: Nitto Denko Corp. - Segment focus
  • Exhibit 89: Nitto Denko Corp. - Key offerings
  • Exhibit 90: QIAGEN NV - Vendor overview
  • Exhibit 91: QIAGEN NV - Product segments
  • Exhibit 92: QIAGEN NV - Organizational developments
  • Exhibit 93: QIAGEN NV - Geographic focus
  • Exhibit 94: QIAGEN NV - Segment focus
  • Exhibit 95: QIAGEN NV - Key offerings
  • Exhibit 96: Sarepta Therapeutics Inc. - Vendor overview
  • Exhibit 97: Sarepta Therapeutics Inc. - Product segments
  • Exhibit 98: Sarepta Therapeutics Inc. - Organizational developments
  • Exhibit 99: Sarepta Therapeutics Inc. - Key offerings
  • Exhibit 100: Thermo Fisher Scientific Inc. - Vendor overview
  • Exhibit 101: Thermo Fisher Scientific Inc. - Business segments
  • Exhibit 102: Thermo Fisher Scientific Inc. - Organizational developments
  • Exhibit 103: Thermo Fisher Scientific Inc. - Geographic focus
  • Exhibit 104: Thermo Fisher Scientific Inc. - Segment focus
  • Exhibit 105: Thermo Fisher Scientific Inc. - Key offerings
  • Exhibit 106: Validation techniques employed for market sizing
  • Exhibit 107: Definition of market positioning of vendors
Back to Top